130 related articles for article (PubMed ID: 29967263)
1. High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific
Kather JN; Charoentong P; Suarez-Carmona M; Herpel E; Klupp F; Ulrich A; Schneider M; Zoernig I; Luedde T; Jaeger D; Poleszczuk J; Halama N
Cancer Res; 2018 Sep; 78(17):5155-5163. PubMed ID: 29967263
[TBL] [Abstract][Full Text] [Related]
2.
Kather JN; Poleszczuk J; Suarez-Carmona M; Krisam J; Charoentong P; Valous NA; Weis CA; Tavernar L; Leiss F; Herpel E; Klupp F; Ulrich A; Schneider M; Marx A; Jäger D; Halama N
Cancer Res; 2017 Nov; 77(22):6442-6452. PubMed ID: 28923860
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.
Du XH; Liu HL; Li L; Xia SY; Ning N; Zou ZY; Teng D; Xiao CH; Li R; Xu YX
Tumour Biol; 2015 Jul; 36(7):5679-85. PubMed ID: 25764087
[TBL] [Abstract][Full Text] [Related]
4. Novel avenues in immunotherapies for colorectal cancer.
Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
[TBL] [Abstract][Full Text] [Related]
5. Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer.
Pancione M; Giordano G; Parcesepe P; Cerulo L; Coppola L; Curatolo AD; Conciatori F; Milella M; Porras A
Curr Med Chem; 2017; 24(14):1383-1402. PubMed ID: 28245767
[TBL] [Abstract][Full Text] [Related]
6. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
7. A Blueprint to Advance Colorectal Cancer Immunotherapies.
Le DT; Hubbard-Lucey VM; Morse MA; Heery CR; Dwyer A; Marsilje TH; Brodsky AN; Chan E; Deming DA; Diaz LA; Fridman WH; Goldberg RM; Hamilton SR; Housseau F; Jaffee EM; Kang SP; Krishnamurthi SS; Lieu CH; Messersmith W; Sears CL; Segal NH; Yang A; Moss RA; Cha E; O'Donnell-Tormey J; Roach N; Davis AQ; McAbee K; Worrall S; Benson AB
Cancer Immunol Res; 2017 Nov; 5(11):942-949. PubMed ID: 29038296
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of the β
Benedicto A; Marquez J; Herrero A; Olaso E; Kolaczkowska E; Arteta B
BMC Cancer; 2017 Dec; 17(1):827. PubMed ID: 29207960
[TBL] [Abstract][Full Text] [Related]
9. The potential role of immunotherapy to treat colorectal cancer.
Amin M; Lockhart AC
Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
[TBL] [Abstract][Full Text] [Related]
10. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.
Roelands J; Kuppen PJK; Vermeulen L; Maccalli C; Decock J; Wang E; Marincola FM; Bedognetti D; Hendrickx W
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064420
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for colorectal cancer: where are we heading?
Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
[TBL] [Abstract][Full Text] [Related]
13. Developments in immunotherapy for gastrointestinal cancer.
Diaz JL; Wanta SM; Fishbein TM; Kroemer A
Minerva Chir; 2015 Aug; 70(4):217-30. PubMed ID: 25916195
[TBL] [Abstract][Full Text] [Related]
14. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
15. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
Kanterman J; Sade-Feldman M; Biton M; Ish-Shalom E; Lasry A; Goldshtein A; Hubert A; Baniyash M
Cancer Res; 2014 Nov; 74(21):6022-35. PubMed ID: 25209187
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer.
Qian DC; Xiao X; Byun J; Suriawinata AA; Her SC; Amos CI; Barth RJ
Clin Cancer Res; 2017 Jan; 23(2):399-406. PubMed ID: 27435399
[TBL] [Abstract][Full Text] [Related]
17. Recent therapeutic advances in the treatment of colorectal cancer.
Ciombor KK; Wu C; Goldberg RM
Annu Rev Med; 2015; 66():83-95. PubMed ID: 25341011
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
[TBL] [Abstract][Full Text] [Related]
19. Coordination of intratumoral immune reaction and human colorectal cancer recurrence.
Camus M; Tosolini M; Mlecnik B; Pagès F; Kirilovsky A; Berger A; Costes A; Bindea G; Charoentong P; Bruneval P; Trajanoski Z; Fridman WH; Galon J
Cancer Res; 2009 Mar; 69(6):2685-93. PubMed ID: 19258510
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer.
Dufait I; Schwarze JK; Liechtenstein T; Leonard W; Jiang H; Escors D; De Ridder M; Breckpot K
Oncotarget; 2015 May; 6(14):12369-82. PubMed ID: 25869209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
